Back to Agenda
Session 4A: Drug Shortages
Session Chair(s)
Norman Schmuff, PhD
Associate Director for Science, OPMA, OPQ
FDA, United States
Drug and other medical product shortages have the potential to adversely affect patient care by delaying treatment or forcing the use of second-choice products. Some recent shortages have involved drugs for life-threatening conditions and, in some cases, the product in shortage has been the only product for the patient’s condition. This is a significant public health problem, one that deserves the concerted attention of government and industry. In this session causes, consequences, and FDA action to address and prevent drug shortages will be discussed.
Speaker(s)
Current Trends in Drug Shortages -- A University of Utah Drug Information Perspective
Erin Fox, PharmD
University of Utah Health Care, United States
Senior Pharmacy Director
FDA's Role in Mitigating Drug Shortages
Valerie Jensen, RPh
FDA, United States
Associate Director, CDER Drug Shortage Program
Economic and Technological Drivers of Generic Sterile Injectable Drug Shortages
Marta E. Wosinska, PhD
The Brookings Institution, United States
Visiting Fellow
Have an account?